Exicure, Inc. (XCUR)
NCM · Healthcare · Biotechnology
$1.73
-0.57%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$11.0M
Shares Outstanding
6.4M
Exchange
NCM
Currency
USD
About Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.4M | -2.4M | -2.3M | -1.6M |
| Net Income | -2.6M | -2.4M | -2.9M | -1.8M |
| Diluted EPS | $-0.41 | $-0.39 | $nan | $-0.29 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 28.8M | 0.00 | 500K | 0.00 |
| Operating Income | -1.8M | -13.1M | -4.9M | -10.1M |
| Net Income | -2.6M | -16.9M | -9.7M | -4.9M |
| Diluted EPS | $-2.80 | $-10.55 | $-4.75 | $-0.79 |